SCHEDULE 13D/A: ADAR1 Capital Management Issues Ultimatum to Keros Therapeutics, Demands Strategic Overhaul and Board Changes

ADAR1 Capital Management, Keros Therapeutics' largest shareholder, has publicly criticized the company's capital allocation and strategic direction, announcing its intention to withhold votes for two directors and advocating for significant business restructuring.

Summary

• ADAR1 Capital Management, holding approximately 13.3% of Keros Therapeutics' outstanding shares, has expressed serious concerns regarding the company's capital allocation, strategic direction, and prolonged underperformance.
• ADAR1 highlights "concerning side effects" and "alarming clinical results" for two of Keros's three drug candidates, KER-012 and KER-065, arguing that further investment risks shareholder value destruction and patient safety.
• The activist investor urges Keros to discontinue development of KER-012 and KER-065 and focus solely on KER-050 (elritercept), which is partnered with Takeda Pharmaceuticals and has a potential peak sales estimate of over $2 billion.
• ADAR1 criticizes Keros's "excessive cost structure," "unfocused strategy," and "unnecessarily bloated balance sheet" with over $720 million in cash as of March 31, 2025, which it believes is being deployed on unproductive initiatives.
• Keros has generated negative total stockholder returns across all relevant timeframes since its IPO, significantly underperforming proxy peers and relevant market and biotechnology sector benchmarks.
• ADAR1 proposes a new approach: restructure the business and reduce headcount by at least 70%, return excess cash to stockholders, and ensure stockholders capture upside from the Takeda partnership via a contingent value right.
• These initiatives are estimated to deliver between $24 and $35 per share in value, encompassing net cash and the net present value of the elritercept partnership.
• ADAR1 intends to WITHHOLD votes for the re-election of Dr. Mary Ann Gray and Dr. Alpna Seth at the Annual Meeting on June 4, 2025, citing their presiding over the company's challenges.
• ADAR1 also supports direct board representation for significant stockholders like itself and Pontifax (11.9% ownership), intending to vote FOR Ran Nussbaum of Pontifax.

Sentiment

Score: 2

Explanation: The document expresses strong negative sentiment from a major shareholder regarding Keros Therapeutics' performance, strategy, and management. It highlights significant underperformance, clinical setbacks, and calls for drastic restructuring and board changes, indicating a highly critical view of the company's current state.

Positives

• KER-050 (elritercept) is believed to have a path to commercialization and could achieve peak sales of more than $2 billion.
• The Takeda licensing partnership is identified as a high-potential opportunity that ADAR1 believes should be managed to maximize value for investors.
• ADAR1 estimates that proposed initiatives (restructuring, cash return, Takeda partnership upside) could ultimately deliver between $24 and $35 per share in value for stockholders.

Negatives

• Keros Therapeutics has generated negative total stockholder returns across every relevant timeframe since its initial public offering.
• The company has significantly underperformed its proxy peers and relevant market and biotechnology sector benchmarks.
• Keros Therapeutics' 1-Year total stockholder return is (77%), compared to Proxy Peers (18%), Nasdaq Composite Index (86%), Nasdaq Biotechnology Index (69%), and SPDR S&P Biotech ETF (62%).
• Keros Therapeutics' 2-Year total stockholder return is (69%), compared to Proxy Peers (20%), Nasdaq Composite Index (116%), Nasdaq Biotechnology Index (64%), and SPDR S&P Biotech ETF (59%).
• Keros Therapeutics' 3-Year total stockholder return is (71%), compared to Proxy Peers (38%), Nasdaq Composite Index (120%), Nasdaq Biotechnology Index (85%), and SPDR S&P Biotech ETF (81%).
• Keros Therapeutics' 4-Year total stockholder return is (75%), compared to Proxy Peers (25%), Nasdaq Composite Index (109%), Nasdaq Biotechnology Index (63%), and SPDR S&P Biotech ETF (36%).
• Keros Therapeutics' 5-Year total stockholder return is (51%), compared to Proxy Peers (9%), Nasdaq Composite Index (159%), Nasdaq Biotechnology Index (54%), and SPDR S&P Biotech ETF (30%).
• Keros Therapeutics' Since IPO total stockholder return is (34%), compared to Proxy Peers (50%), Nasdaq Composite Index (167%), Nasdaq Biotechnology Index (54%), and SPDR S&P Biotech ETF (32%).
• Two of Keros's three drug candidates, KER-012 and KER-065, have demonstrated "concerning side effects" and "alarming clinical results."
• The company is criticized for an "excessive cost structure," an "unfocused strategy," and an "unnecessarily bloated balance sheet" with over $720 million in cash as of March 31, 2025, which ADAR1 believes is being deployed on unproductive or misguided initiatives.
• The Board has rejected ADAR1's recommendations and offer of assistance, appearing content to continue a path that ADAR1 believes is actively destroying shareholder value.

Risks

• Continued investment in KER-012 and KER-065 programs risks further shareholder value destruction due to concerning clinical results and side effects.
• Further development of KER-012 and KER-065 could potentially put patients at risk due to demonstrated concerning side effects.
• The company's current market value barely reflects the estimated net present value of potential milestone payments from the Takeda partnership, suggesting investors assign zero value to the rest of Keros's pipeline.
• There is a risk that the company will deploy its substantial capital (more than $720 million as of March 31, 2025) on unproductive or misguided initiatives.
• Without a change in oversight and strategy, the company's poor performance and depressed valuation are expected to persist.

Future Outlook

ADAR1 Capital Management believes that Keros Therapeutics' KER-050 (elritercept) has a clear path to commercialization and could achieve peak sales exceeding $2 billion. However, ADAR1 warns that without a significant change in oversight and strategy, the company's poor performance and depressed valuation are likely to persist. ADAR1 projects that its proposed initiatives could deliver between $24 and $35 per share in value for stockholders.

Management Comments

• "Keros Therapeutics (Keros or the Company) is at a crossroads."
• "Two of the Company’s three drug candidates, KER-012 and KER-065, have demonstrated concerning side effects in clinical trials. In our view, any further development would be dilutive to stockholder value and, potentially, put patients at risk."
• "The Company has dismissed our recommendations and continues to operate with what we believe is an excessive cost structure, an unfocused strategy, and an unnecessarily bloated balance sheet with too much cash."
• "Rather than right-sizing its capital structure and concentrating on high-potential opportunities, the Company has persisted with developing programs that we believe are value-destructive."
• "We invested in Keros because we saw enormous potential. But in our view, that potential is being squandered."
• "The Company’s current market value barely reflects our estimate of the net present value of potential milestone payments from the Takeda partnership, suggesting that investors assign zero value to the rest of Keros’s pipeline and believe that the Company will deploy its substantial capital—more than $720 million as of March 31, 2025—on unproductive or misguided initiatives."
• "We think a new approach is urgently needed and the best path forward for Keros and its stockholders is to: Restructure the business and reduce headcount by at least 70%; Return excess cash to stockholders, preserving only what is necessary to support high-confidence opportunities; and Ensure that stockholders capture the upside from the Takeda partnership through a contingent value right or similar mechanism."
• "We believe these initiatives could ultimately deliver between $24 and $35 per share in value for stockholders, encompassing net cash value and the net present value of the elritercept partnership."
• "The Board rejected our offer of assistance and appears content to continue down a path that, in our view, is actively destroying shareholder value."
• "We see no reason to be optimistic about the prospects of KER-012 or KER-065."
• "Without a change in oversight and strategy, we believe the Company’s poor performance and depressed valuation will persist."
• "Keros needs a Board that will ask tough questions, challenge management, and act with a sense of urgency. It is time for accountability."

Industry Context

This document highlights a common challenge in the biotechnology sector where promising drug pipelines face clinical setbacks, leading to significant value destruction. It also exemplifies shareholder activism in biotech, where investors push for strategic shifts, cost reductions, and capital returns when they perceive management is misallocating resources or failing to deliver on potential. The focus on a single promising asset (KER-050) and a major partnership (Takeda) is typical for biotech companies seeking to de-risk their pipeline and secure funding. The underperformance against biotech indices and peers suggests Keros is struggling more than the broader sector.

Comparison to Industry Standards

• Keros Therapeutics has generated negative total stockholder returns across all relevant timeframes since its IPO, significantly underperforming its proxy peers and relevant market and biotechnology sector benchmarks.
• Compared to its Proxy Peers (Akero Therapeutics, Arcturus Therapeutics, Crinetics Pharmaceuticals, Editas Medicine, Geron Corp., IDEAYA Biosciences, Iovance Biotherapeutics, KalVista Pharmaceuticals, Kura Oncology, Mersana Therapeutics, Morphic Holding, Protagonist Therapeutics, Replimune Group, Rocket Pharmaceuticals, Scholar Rock Holding Corp., Springworks Therapeutics, Syndax Pharmaceuticals and Zentalis Pharmaceuticals), Keros underperformed by a median of 59% over 1 year, 49% over 2 years, 33% over 3 years, 50% over 4 years, 42% over 5 years, and 16% since IPO.
• Compared to the Nasdaq Composite Index, Keros underperformed by 9% over 1 year, 47% over 2 years, 49% over 3 years, 34% over 4 years, 108% over 5 years, and 133% since IPO.
• Compared to the Nasdaq Biotechnology Index, Keros underperformed by 8% over 1 year, 5% over 2 years, 14% over 3 years, 12% over 4 years, 3% over 5 years, and 20% since IPO.
• Compared to the SPDR S&P Biotech ETF, Keros underperformed by 15% over 1 year, 10% over 2 years, 10% over 3 years, 39% over 4 years, 21% over 5 years, and 2% since IPO.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Significant potential for value creation (estimated $24-$35 per share) if ADAR1's proposed changes are implemented, but current significant value destruction and underperformance. The proposed return of excess cash would directly benefit shareholders.
• Employees: Potential for significant headcount reduction (at least 70%) if ADAR1's recommendations are adopted, leading to job losses.
• Patients: Concerns raised about potential risks to patients from continued development of KER-012 and KER-065 due to "concerning side effects."
• Management/Board: Direct challenge to current management and board members, with calls for accountability and potential removal/non-re-election of directors.
• Takeda Pharmaceuticals: The partnership with Takeda on KER-050 is highlighted as the primary value driver, and ADAR1 emphasizes maximizing its value, which could impact the partnership's strategic direction.

Next Steps

• Keros Therapeutics' Annual Meeting of Stockholders is scheduled for June 4, 2025.
• ADAR1 Capital Management intends to vote WITHHOLD on the re-election of Dr. Mary Ann Gray and Dr. Alpna Seth at the Annual Meeting.
• ADAR1 Capital Management intends to vote FOR Ran Nussbaum for election to the Board.
• ADAR1 urges Keros to restructure the business and reduce headcount by at least 70%.
• ADAR1 urges Keros to return excess cash to stockholders.
• ADAR1 urges Keros to ensure stockholders capture the upside from the Takeda partnership through a contingent value right or similar mechanism.

Key Dates

Recommendation

Keywords

Keros Therapeutics, KROS, ADAR1 Capital Management, Shareholder Activism, Biotech, Pharmaceuticals, Drug Development, Clinical Trials, KER-012, KER-065, KER-050, Elritercept, Takeda Pharmaceuticals, Corporate Governance, Board of Directors, Shareholder Value, Capital Allocation, Headcount Reduction, Cash Return, Contingent Value Right, Proxy Fight, Schedule 13D